Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 24INDUSTRY 17NETWORK 3UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gastrointestinal 2

Conditions

Breast Neoplasms 3

Interventions

Cyclophosphamide 42Docetaxel 33Paclitaxel 31Tamoxifen 29Doxorubicin 29Trastuzumab 25Radiotherapy 21Epirubicin 16Letrozole 15Anastrozole 12exemestane 11Fluorouracil 11Capecitabine 10Bevacizumab 10palbociclib 9Immunohistochemistry 9Fulvestrant 9Filgrastim 9Lapatinib 8Zoledronic Acid 7Methotrexate 7Magnetic Resonance Spectroscopy 7Gene Expression Profiling 7pertuzumab 6Triptorelin Pamoate 6Taxes 6Surgical Procedures, Operative 6Microarray Analysis 6Goserelin 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × neratinib × Breast × Clear all
NCT02236000 2023-01-26

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

NSABP Foundation Inc

Phase 1/2 Completed
49 enrolled 17 charts
Breast

Breast Neoplasms

NCT01008150 2021-10-25

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

NSABP Foundation Inc

Phase 2 Completed
141 enrolled 16 charts
Breast

Breast Neoplasms

NCT01423123 2014-07-08

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

NSABP Foundation Inc

Phase 1 Completed
21 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡